{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Preparation/Handling/Storage/Accountabilit;', 'body of the', 'Section 7.1.1.1, Participants Meeting Virologic', 'protocol', 'Management Criteria', 'Section 8, Study Assessments and Procedures', 'Section 8.2.4, Clinical Safety Laboratory Assessments', 'Section 8.3, Adverse events (AE) and serious adverse', 'events (SAEs)', 'Section 11.7, Appendix 7: Clinical Laboratory Tests', 'Removed text, Added text', 'Section 6.8, Treatment after the end of the study', 'To correct an', 'administrative', 'error and to aid', 'clarity', 'Added references', 'Section 10, References', 'To reflect new', 'text added to the', 'amendment', 'Section 11.6, Appendix 6, Prohibited Medications', 'Added fampridine and', 'related text and clarifications', 'To align with', 'current', 'Investigator', 'Brochure version', '13 and aid clarity', 'Section 11.9.1, Liver Chemistry Stopping Criteria:', 'Added laboratory', 'To align with', 'assessments', 'Required Actions and Follow up Assessments', 'updated', 'guidance', 'Added new sections to', 'Section 11.13, Appendix 13: Country-specific', 'To consolidate', 'Requirements', 'describe previous country', 'Sweden/Denmark', 'specific amendments for', 'Sweden/Denmark and', 'into the global', 'amendment and', 'China. Sweden/Denmark will', 'now be incorporated into this', 'provide clarity on', 'past country', 'global amendment.', 'specific protocol', 'amendments', 'Section 11.14, Appendix 14: COVID-19 Pandemic and', 'Added appendix', 'To summarize', 'Clinical Trial Continuity', 'COVID-19 related', 'patient', 'management', 'updates that', 'were previously', 'communicated in', 'a memo to', 'investigators', '6']['2017N331008_0', 'CONFIDENTIAL', '208090', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', '4', '1.', 'PROTOCOL SUMMARY', '11', '1.1.', 'Synopsis', '11', '1.2.', 'Schema', '15', '1.3.', 'Schedule of Activities (SoA)', '16', '2.', 'INTRODUCTION', '21', '2.1.', 'Study Rationale', '22', '2.2.', 'Background', '23', '2.3.', 'Benefit/Risk Assessment', '25', '2.3.1.', 'Risk Assessment', '26', '2.3.2.', 'Benefit Assessment', '30', '2.3.3.', 'Overall Benefit: Risk Conclusion', '30', '3.', 'OBJECTIVES AND ENDPOINTS', '31', '4.', 'STUDY DESIGN', '33', '4.1.', 'Overall Design', '33', '4.2.', 'Number of Participants', '34', '4.3.', 'Participant and Study Completion', '34', '4.4.', 'Scientific Rationale for Study Design', '35', '4.5.', 'Justification for Dose', '36', '5.', 'STUDY POPULATION', '38', '5.1.', 'Inclusion Criteria', '38', '5.2.', 'Exclusion Criteria', '40', '5.3.', 'Lifestyle Restrictions', '43', '5.4.', 'Screen Failures', '43', '6.', 'STUDY INTERVENTION', '43', '6.1.', 'Study Interventions Administered', '45', '6.2.', 'Dose Modification', '45', '6.3.', 'Method of Treatment Assignment', '45', '6.4.', 'Blinding', '46', '6.5.', 'Preparation/Handling/Storage/Accountability', '46', '6.6.', 'Treatment Compliance', '47', '6.7.', 'Concomitant Therapy', '47', '6.7.1.', 'Permitted Medications and Non-Drug Therapies', '47', '6.8.', 'Treatment after the End of the Study', '48', '7.', 'DISCONTINUATION CRITERIA', '49', '7.1.', 'Discontinuation of Study Intervention', '49', '7.1.1.', 'Virologic Criteria for Participant Management and Viral', 'Resistance Testing', '49', '7.1.1.1.', 'Participants Meeting Virologic Management', 'Criteria', '49', '7']\n\n###\n\n", "completion": "END"}